Day One Biopharmaceuticals I (DAWN)

$15.92

+1.05

(+7.06%)

Market is closed - opens 7 PM, 24 Jul 2024

Performance

  • $14.75
    $15.95
    $15.92
    downward going graph

    7.34%

    Downside

    Day's Volatility :7.49%

    Upside

    0.16%

    downward going graph
  • $9.67
    $18.07
    $15.92
    downward going graph

    39.26%

    Downside

    52 Weeks Volatility :46.49%

    Upside

    11.9%

    downward going graph

Returns

PeriodDay One Biopharmaceuticals ISector (Health Care)Index (Russel 2000)
3 Months
-10.64%
5.3%
0.0%
6 Months
8.15%
6.3%
0.0%
1 Year
25.91%
9.2%
0.0%
3 Years
-34.29%
13.1%
-19.9%

Highlights

Market Capitalization
1.3B
Book Value
$3.4
Earnings Per Share (EPS)
-2.5
Wall Street Target Price
35.75
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-42.67%
Return On Equity TTM
-69.97%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-221.9M
Diluted Eps TTM
-2.5
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.7
EPS Estimate Next Year
-2.17
EPS Estimate Current Quarter
-0.66
EPS Estimate Next Quarter
-0.67

Analyst Recommendation

Buy
    82%Buy
    11%Hold
    5%Sell
Based on 17 Wall street analysts offering stock ratings for Day One Biopharmaceuticals I(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
14
Hold
2
2
2
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 124.56%

Current $15.92
Target $35.75

Technicals Summary

Sell

Neutral

Buy

Day One Biopharmaceuticals I is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Day One Biopharmaceuticals I
Day One Biopharmaceuticals I
9.9%
8.15%
25.91%
-34.29%
-31.63%
Moderna, Inc.
Moderna, Inc.
-10.58%
20.19%
-0.41%
-64.88%
800.74%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.55%
12.06%
47.12%
82.44%
245.9%
Novo Nordisk A/s
Novo Nordisk A/s
-6.4%
26.39%
64.35%
193.51%
440.83%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.41%
12.78%
38.89%
147.34%
182.99%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Day One Biopharmaceuticals I
Day One Biopharmaceuticals I
3.54
NA
NA
-2.7
-0.7
-0.43
NA
3.4
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.45
31.45
1.46
44.4
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.05
45.05
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Day One Biopharmaceuticals I
Day One Biopharmaceuticals I
Buy
$1.3B
-31.63%
3.54
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.4B
800.74%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.2B
245.9%
31.45
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.7B
440.83%
45.05
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
182.99%
31.94
39.46%

Insights on Day One Biopharmaceuticals I

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 60.8% return, outperforming this stock by 37.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 193.5% return, outperforming this stock by 227.8%

Institutional Holdings

  • RA Capital Management, LLC

    8.94%
  • BlackRock Inc

    5.76%
  • Vanguard Group Inc

    5.46%
  • FMR Inc

    5.04%
  • Franklin Resources Inc

    4.36%
  • State Street Corporation

    3.31%

Company Information

day one biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. we are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. we are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.

Organization
Day One Biopharmaceuticals I
Employees
174
CEO
Dr. Jeremy Bender M.B.A., Ph.D.
Industry
Healthcare

FAQs